Röllig, Christoph <br/><br/>
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.  [electronic resource] 

 -  The Lancet. Oncology  Dec 2015 
 - 1691-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)00362-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Antibiotics, Antineoplastic--therapeutic use<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Chemotherapy, Adjuvant<br/>Cytarabine--therapeutic use<br/>Daunorubicin--therapeutic use<br/>Disease Progression<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Germany<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Kaplan-Meier Estimate<br/>Leukemia, Myeloid, Acute--diagnosis<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy--adverse effects<br/>Niacinamide--adverse effects<br/>Phenylurea Compounds--adverse effects<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--adverse effects<br/>Recurrence<br/>Risk Factors<br/>Sorafenib<br/>Time Factors<br/>Transplantation, Homologous<br/>Treatment Outcome